AbbVie, a research based global biopharmaceutical company, announced this week that the FDA has issued approval for ORILISSATM, the company's trade name for elagolix, for...
Findings from a recent study suggest that rethinking the delivery mechanism for buprenorphine may enhance its effectiveness in treating opioid use disorder (OUD), now estimated...
Findings from a recent study published in the journal Annals of Allergy, Asthma and Immunology conclude that atopic dermatitis, or eczema, imposes a...
NSAID use around the time of conception can significantly increase the risk of miscarriage during the first 8 weeks of pregnancy, according to conclusions from...
Researchers from Washington University School of Medicine, St. Louis, report that receptors on immune cells may be a more effective therapeutic target than nerve cells...